| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03591744 Details | 2018-12-19 Interventional | 1 | 0 | BB 1101 Bortezomib Daratumumab Dexamethasone Dexamethasone a… Doxorubicin Ichthammol Lenalidomide Liposomal doxor… Leukemia Leukemia, Plasm… Plasma Cell Leu… | Budgetary constraints - | |||
| NCT02556463 Details | 2018-12-19 Interventional | 1 | 53 | Durvalumab MEDI9197 Neoplasms CTCL Cancer Solid Tumors | Company strategy - | |||
| NCT02365493 Details | 2018-12-19 Interventional | 3 | 358 | Cefazolin Cloxacillin Floxacillin Lactams beta-Lactams Staphylococcal … Methicillin-Res… | Recommendation of the Data Safety Monitoring Committee - | |||
| NCT02311777 Details | 2018-12-19 Interventional | 3 | 0 | Ketamine Pregabalin Phantom Limb Phantom Pain | Preoperative period is very short time - | |||
| NCT01552798 Details | 2018-12-19 Interventional | 3 | 9 | Acetaminophen Aspirin Headache Tension-Type He… | - - | |||
| NCT01523639 2011-001010-34 Details | 2018-12-19 Interventional | 2 | 8 | Metformin Colorectal Neop… Fatty Liver Colorectal Canc… Steatohepatitis | Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013.
ABCSG guaranteed completed treatment period for ethical reasons. - | |||
| NCT01514838 Details | 2018-12-17 Interventional | 3 | 46 | Acarbose Ipragliflozin Diabetes Mellit… Diabetes Mellit… Type II Diabete… | Discontinued due to company's strategic reason - | |||
| NCT03398018 Details | 2018-12-14 Interventional | 4 | 0 | Adrenocorticotr… Dry Eye Syndrom… Keratoconjuncti… Keratoconjuncti… | Change of direction - | |||
| NCT02374099 Details | 2018-12-14 Interventional | 2 | 97 | Azacitidine Cc-486 Fulvestrant Breast Neoplasm… | - - | |||
| NCT02236481 Details | 2018-12-14 Interventional | 4 | 41 | Interleukin 1 R… Arthritis Arthritis, Rheu… Diabetes Mellit… Diabetes Mellit… | Decision of the Sponsor for Early Benefits - | |||
| NCT00128895 Details | 2018-12-13 Interventional | 4 | [1 Refs] | 131 | Azathioprine Vasculitis | - - | ||
| NCT02785900 2015-003482-28 Details | 2018-12-12 Interventional | 3 | 240 | Azacitidine Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A
arm versus the control arm - | |||
| NCT02722083 Details | 2018-12-12 Interventional | 2 | 1 | Chlorpheniramin… Rhinitis Rhinitis, Aller… | - - | |||
| NCT03349346 2017-001468-39 Details | 2018-12-11 Interventional | 1 | 0 | Carboplatin Etoposide Idelalisib Ifosfamide Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… Mediastinal B-c… | The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the
grounds that idelalisib is likely to be unsafe in paediatrics - | |||
| NCT00924807 Details | 2018-12-11 Interventional | 1/2 | 4 | Bicalutamide Leuprolide Sorafenib Prostatic Neopl… Prostate Cancer | Sponsor closed the trial Data of zero ("0") participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study. Early termination leading to small number of subjects analyzed. | |||
| NCT01374217 Details | 2018-12-10 Interventional | 2 | 14 | Clarithromycin Dexamethasone Lenalidomide Tadalafil Multiple Myelom… Neoplasms, Plas… | early stopping rule - | |||
| NCT03531281 Details | 2018-12-07 Interventional | 1 | 0 | Cyclophosphamid… Etoposide Etoposide phosp… Mitogens Podophyllotoxin Sirolimus Tacrolimus Hematologic Neo… Hematopoietic C… Hematopoietic a… | Administratively withdrawn - | |||
| NCT02401594 2015-000981-70 Details | 2018-12-07 Interventional | 3 | 3608 | Enoxaparin Rivaroxaban Non-major Ortho… | Remaining outdated treatments and additional costs too high for new manufacturing - | |||
| NCT01281956 Details | 2018-12-07 Interventional | 2 | 12 | Naluzotan Epilepsies, Par… Epilepsy Epilepsy, Tempo… Partial Epileps… | - - | |||
| NCT00100828 Details | 2018-12-06 Interventional | 2 | 6 | Irinotecan Thyroid Neoplas… Head and Neck C… | Closed due to early stopping rule - |